Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Gross Profit (2016 - 2025)

Historic Gross Profit for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$59654.0.

  • China Pharma Holdings' Gross Profit rose 8852.03% to -$59654.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$442847.0, marking a year-over-year increase of 7673.82%. This contributed to the annual value of -$2.0 million for FY2024, which is 60642.26% down from last year.
  • As of Q3 2025, China Pharma Holdings' Gross Profit stood at -$59654.0, which was up 8852.03% from -$87010.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Gross Profit high stood at $301936.0 for Q4 2021, and its period low was -$1.0 million during Q2 2024.
  • Moreover, its 5-year median value for Gross Profit was -$137756.0 (2022), whereas its average is -$141794.9.
  • In the last 5 years, China Pharma Holdings' Gross Profit tumbled by 72801.08% in 2021 and then skyrocketed by 20499.41% in 2023.
  • China Pharma Holdings' Gross Profit (Quarter) stood at $301936.0 in 2021, then tumbled by 85.86% to $42682.0 in 2022, then crashed by 285.46% to -$79158.0 in 2023, then plummeted by 102.87% to -$160589.0 in 2024, then surged by 62.85% to -$59654.0 in 2025.
  • Its last three reported values are -$59654.0 in Q3 2025, -$87010.0 for Q2 2025, and -$136061.0 during Q1 2025.